Sripriyalakshmi S, Jose Pinkybel, Ravindran Aswathy, Anjali C H
Center for Nanotechnology and Advanced Biomaterials (CeNTAB), School of Chemical and Biotechnology, SASTRA University, Tirumalaisamudram, Thanjavur, 613401, Tamilnadu, India.
Cell Biochem Biophys. 2014 Sep;70(1):17-26. doi: 10.1007/s12013-014-9896-5.
Engineered nanoparticles that can facilitate drug formulation and passively target tumours have been under extensive research in recent years. These successes have driven a new wave of significant innovation in the generation of advanced particles. The fate and transport of diagnostic nanoparticles would significantly depend on nonselective drug delivery, and hence the use of high drug dosage is implemented. In this perspective, nanocarrier-based drug targeting strategies can be used which improve the selective delivery of drugs to the site of action, i.e. drug targeting. Pharmaceutical industries majorly focus on reducing the toxicity and side effects of drugs but only recently it has been realised that carrier systems themselves may pose risks to the patient. Proteins are compatible with biological systems and they are biodegradable. They offer a multitude of moieties for modifications to tailor drug binding, imaging or targeting entities. Thus, protein nanoparticles provide outstanding contributions as a carrier for drug delivery systems. This review summarises recent progress in particle-based therapeutic delivery and discusses important concepts in particle design and biological barriers for developing the next generation of particles drug delivery systems.
近年来，能够促进药物制剂并被动靶向肿瘤的工程纳米颗粒一直处于广泛研究之中。这些成果推动了先进颗粒生成方面的新一轮重大创新。诊断纳米颗粒的命运和运输将极大地依赖于非选择性药物递送，因此会使用高剂量药物。从这个角度来看，可以采用基于纳米载体的药物靶向策略，以改善药物向作用部位的选择性递送，即药物靶向。制药行业主要致力于降低药物的毒性和副作用，但直到最近才意识到载体系统本身可能对患者构成风险。蛋白质与生物系统兼容且可生物降解。它们提供了大量用于修饰的基团，以定制药物结合、成像或靶向实体。因此，蛋白质纳米颗粒作为药物递送系统的载体做出了杰出贡献。本综述总结了基于颗粒的治疗性递送的最新进展，并讨论了颗粒设计和生物屏障方面的重要概念，以开发下一代颗粒药物递送系统。
